EICHORPublic-registry site landscape for NCT07295951, “A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia”, a Acute Lymphoblastic Leukemia study sponsored by Janssen Research & Development, LLC. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07295951 (registry record) |
| Study title | A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia |
| Official title | An Open-Label Study to Investigate the Absorption, Metabolism, And Excretion (AME) Of 14C-Bleximenib (JNJ-75276617) in Participants With Acute Leukemia |
| Sponsor | Janssen Research & Development, LLC |
| Condition(s) | Acute Lymphoblastic Leukemia; Acute Leukemias; Acute Myeloid Leukemia |
| Phase | PHASE1 |
| Listed sites | 1 |
| Site countries | United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT07295951.
Eichor generates a preliminary site-risk snapshot for NCT07295951 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Acute Lymphoblastic Leukemia trials
More from Janssen Research & Development, LLC
← Eichor home · All tracked trials · Acute Lymphoblastic Leukemia studies · Weekly briefs
